GET DAILY SIGNALSFortrea Holdings (FTRE) Delivers Earnings Beat Amid -10% Share Reaction
Key Takeaways
- Fortrea Holdings (FTRE) reported third-quarter 2026 revenue of $691.5 million, down 1.4% year over year but ahead of consensus estimates of roughly $671 million.
- Adjusted earnings per share (EPS) came in at $0.28, beating analyst expectations of about $0.22 by roughly 29%.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) rose 14.4% year over year to $58.0 million, with margins expanding to 8.4%.
- The company recorded a book-to-bill ratio of 1.12x, signaling continued momentum in new business awards as it executes its return-to-growth strategy.
- Management raised and narrowed its full-year 2026 guidance, now projecting revenue of $2.665 billion to $2.690 billion.
- Despite the beats and guidance raise, shares fell more than 10% on the day, reflecting investor focus on the year-over-year revenue decline and a backlog adjustment.
- For more details on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
- You can also explore Trending AI Robots to see AI-driven trading strategies currently capturing market attention.
Earnings Context and Why It Matters
Fortrea Holdings (FTRE) is a leading global contract research organization (CRO) that helps pharmaceutical and biotechnology companies run clinical trials and drug development programs. The third-quarter 2026 report carries extra weight because the company remains in the middle of a multi-year "return to growth" effort after spinning off as an independent business. Investors have been watching closely for evidence that stronger bookings are translating into revenue growth, margin expansion, and healthier cash flow. A prior-year quarter that included sizable impairment charges and a net loss made this year's results a key test of whether operational discipline and commercial execution are genuinely improving the business. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the three months ended September 30, 2026, Fortrea Holdings (FTRE) reported revenue of $691.5 million, compared with $701.3 million in the same period a year earlier. The 1.4% decline primarily reflected slower conversion within the pass-through portion of backlog. On a generally accepted accounting principles (GAAP) basis, the company posted net income of $0.6 million, or $0.01 per diluted share, versus a net loss of $15.9 million, or $0.17 per share, in the prior-year quarter.
On an adjusted basis, EPS reached $0.28, comfortably above consensus expectations near $0.22. Adjusted EBITDA climbed to $58.0 million, up from $50.7 million a year ago, with adjusted EBITDA margin expanding by 120 basis points to 8.4%. Net new business awards totaled $773 million, producing a book-to-bill ratio of 1.12x. Operating cash flow was $60.8 million and free cash flow was $52.5 million.
Management also raised and narrowed its full-year 2026 outlook, now expecting revenue of $2.665 billion to $2.690 billion and adjusted EBITDA of $210 million to $218 million. The company reduced reported backlog by $558 million following a contract review, leaving adjusted backlog at $7.316 billion.
Market Reaction and Investor Sentiment
Despite headline beats on both revenue and adjusted EPS, Fortrea Holdings (FTRE) shares dropped more than 10% on the day of the announcement. The selloff highlighted the market's sensitivity to the year-over-year revenue decline and the $558 million reduction in reported backlog tied to a contract review. While the book-to-bill ratio above 1.0x and the guidance raise were positive signals, investors appeared to weigh the near-term top-line pressure and the backlog adjustment more heavily. The reaction underscores that, in the CRO sector, demonstrated conversion of bookings into revenue remains a central concern, even as profitability and cash generation improve.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will be watching whether Fortrea Holdings (FTRE) can convert its improving demand into sustained revenue growth. Management has pointed to a broader and stronger commercial pipeline, supported by investments in clinical pharmacology, technology, and AI adoption. The recent acquisition of the Early Phase Services business from Worldwide Clinical Trials adds bioanalytical and clinical research capacity, which the company expects to support its early development platform.
Margin trajectory is another key focus. Fortrea has indicated that low single-digit service-fee revenue growth should begin to generate operating leverage, with more meaningful expansion as growth approaches the mid-single digits. The company's stated objective of reaching mid-teens adjusted EBITDA margins will depend on favorable business mix, improved utilization, and disciplined cost management.
Balance-sheet progress also remains on the radar. Net leverage declined to 3.9x, and net days sales outstanding (DSO) improved to 15 days, reflecting stronger working-capital management. Continued deleveraging and positive free cash flow in the fourth quarter will be important signals of financial health. Investors should monitor future book-to-bill ratios, backlog conversion rates, and any further adjustments to guidance as the turnaround strategy unfolds.
Using Tickeron’s AI Tools for Deeper Analysis
In my own work, I frequently rely on Tickeron’s AI Screener to quickly filter stocks by fundamentals, technical patterns, and industry trends. It helps surface comparable names in the CRO space and highlights potential relative strength or weakness that might not be obvious from earnings releases alone. This kind of tool keeps the research process efficient without replacing careful fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for FTRE shows an upward move is likely
FTRE's Aroon Indicator triggered a bullish signal on October 29, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 120 similar instances where the Aroon Indicator showed a similar pattern. In 103 of the 120 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on FTRE as a result. In 41 of 54 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
Following a +8.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where FTRE advanced for three days, in 155 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The 10-day RSI Indicator for FTRE moved out of overbought territory on October 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In 20 of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FTRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
FTRE broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.197) is normal, around the industry mean (3.070). P/E Ratio (-27.873) is within average values for comparable stocks, (-1.257). Projected Growth (PEG Ratio) (0.344) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.491) among similar stocks. P/S Ratio (0.695) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. FTRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FTRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement